Evidence map›Paper›PMID 33063955›Full record

ArticleJournal of cellular and molecular medicine2020

Zinc Finger Protein ZBTB20 protects against cardiac remodelling post-myocardial infarction via ROS-TNFα/ASK1/JNK pathway regulation.

Fangfang Li, Yiming Yang, Chuanyou Xue, Mengtong Tan, Lu Xu, Jianbo Gao, Luhong Xu, Jing Zong, Wenhao Qian

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cellular and molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Recent Advances in Gene Therapy for Cardiac Tissue Regeneration.International journal of molecular sciences · 2021
    Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Fangfang LiDepartment of Cardiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Yiming YangDepartment of Cardiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Chuanyou XueDepartment of Cardiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Mengtong TanDepartment of Cardiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Lu XuDepartment of Cardiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Jianbo GaoDepartment of Cardiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Luhong XuDepartment of Cardiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Jing ZongDepartment of Cardiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Wenhao QianDepartment of Cardiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.ORCID 0000-0003-2329-3697
Xuzhou Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aims to determine the efficacy of Zinc finger protein ZBTB20 in treatment of post-infarction cardiac remodelling. For this purpose, left anterior descending (LAD) ligation was operated on mice to induce myocardial infarction (MI) with sham control group as contrast and adeno-associated virus (AAV9) system was used to deliver ZBTB20 to mouse heart by myocardial injection with vehicle-injected control group as contrast two weeks before MI surgery. Then four weeks after MI, vehicle-treated mice with left ventricular (LV) remodelling underwent deterioration of cardiac function, with symptoms of hypertrophy, interstitial fibrosis, inflammation and apoptosis. The vehicle-injected mice also showed increase of infarct size and decrease of survival rate. Meanwhile, the ZBTB20-overexpressed mice displayed improvement after MI. Moreover, the anti-apoptosis effect of ZBTB20 was further confirmed in H9c2 cells subjected to hypoxia in vitro. Further study suggested that ZBTB20 exerts cardioprotection by inhibiting tumour necrosis factor α/apoptosis signal-regulating kinase 1 (ASK1)/c-Jun N-terminal kinase 1/2 (JNK1/2) signalling, which was confirmed by shRNA-JNK adenoviruses transfection or a JNK activator in vitro as well as ASK1 overexpression in vivo. In summary, our data suggest that ZBTB20 could alleviate cardiac remodelling post-MI. Thus, administration of ZBTB20 can be considered as a promising treatment strategy for heart failure post-MI. Significance Statement: ZBTB20 could alleviate cardiac remodelling post-MI via inhibition of ASK1/JNK1/2 signalling.

Indexed as

Gene Expression RegulationAnimalsAnimals, NewbornApoptosisCells, CulturedCoronary VesselsDependovirusFibroblastsHeart FailureHypoxiaMaleMAP Kinase Kinase Kinase 5MAP Kinase Signaling SystemMiceMice, Inbred C57BLMitogen-Activated Protein Kinase 8Map3k5 protein, mouseMAP Kinase Kinase Kinase 5Mitogen-Activated Protein Kinase 8Reactive Oxygen SpeciesTranscription FactorsTumor Necrosis Factor-alphaZbtb20 protein, mouseapoptosisASK1/JNK1/2cardiac remodellingmyocardial infarctionZBTB20

Identifiers

PMID33063955
PMCPMC7701508
OpenAlexW3093182689

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.